Clinical and quantitative electroencephalographical effects of MK 940.
D000275:Adjustment Disorders / Q000188:drug therapy; D000328:Adult; D000639:Amitriptyline / Q000009:adverse effects* / Q000627:therapeutic use*; D000856:Anorexia Nervosa / Q000139:chemically induced; D001288:Attention / Q000187:drug effects; D002986:Clinical Trials as Topic; D003243:Consciousness / Q000187:drug effects; D003863:Depression / Q000188:drug therapy*; D003864:Depression, Chemical; D003986:Dibenzocycloheptenes / Q000009:adverse effects* / Q000627:therapeutic use*; D004569:Electroencephalography; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D001523:Mental Disorders / Q000188:drug therapy*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy; D010146:Pain / Q000139:chemically induced; D010259:Paranoid Disorders / Q000188:drug therapy; D010919:Placebos; D012472:Salivation / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013268:Stimulation, Chemical; D014839:Vomiting / Q000139:chemically induced
D003986:Dibenzocycloheptenes; D010919:Placebos; D000639:Amitriptyline